We have evaluated mitochondrial (mt) DNA content in CD4 and CD8 peripheral blood lymphocytes (PBLs) from HIV-infected patients taking highly active antiretroviral therapy (HAART) who display different types of adipose tissue alterations. A cross-sectional study was performed in a total of 23 patients with lipodystrophy (LD): nine patients with fat accumulation, six patients with fat loss, eight patients with combined form, who were compared to 11 individuals infected by HIV without LD (HIV-positive) and 10 seronegative controls (CTRL). PBLs were obtained by standard methods, that is, gradient density centrifugation on Ficoll, and CD4 or CD8 cells were positively isolated by magnetic sorting to eliminate the contamination of platelets. mtDNA content was then measured by an original assay based upon real-time PCR. mtDNA content was significantly increased in CD4 T cells from patients with LD, while no differences were present between CD4 and CD8 cells from HIV-positive and CTRL individuals. Nor were any differences found when comparing LD or HIV-positive patients treated with stavudine or zidovudine, or taking D-drugs or non D-drugs. Patients with fat accumulation had significantly higher mtDNA content compared to HIV-positive and CTRL, this phenomenon regarding both CD4 and CD8 PBLs. Considering all HIV-positive patients (including LD), mtDNA content showed a significant, positive correlation with cholesterolaemia but not with triglyceridaemia and glycaemia. Relatively high mtDNA content in LD patients, as well as the correlation between mtDNA content and cholesterol in all HIV-positive subjects, suggest the involvement of mitochondria in such a pathology. However, further studies are needed to confirm these initial observations and ascertain whether the quantification of mtDNA in PBL is a useful and reliable marker to investigate and monitor HAART-related changes in fat distribution.
References
1.
CossarizzaA., TroianoL., & MussiniC.Mitochondria and HIV infection: the first decade. Journal of Biological Regulators & Homeostatic Agents2002; 16: 18–24.
2.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., & ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999; 354: 1112–1115.
3.
CôtéH.C.F., BrummeZ.L., CraibK.J.P., AlexanderC.S., WynhovenB., TingL., WongH., HarrisM., HarriganP.R., O'ShaughnessyM.V., & MontanerJ.S.Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine2002; 346: 811–820.
4.
CossarizzaA., PintiM., MorettiL., BricalliD., BianchiR., TroianoL., Garcia FernandezM., BalliF., BrambillaP., MussiniC., & ViganòA.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically-infected HIV+ children with HAART-related lipodystrophy. Journal of Infectious Diseases2002; 185: 299–305.
5.
McComseyG., TanD.J., LedermanM., WilsonE., & WongL.J.Analysis of mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with of without lipoatrophy. AIDS2002; 16: 513–518.
6.
ShikumaC.M., HuN., YostF., WaslienC., ShimizuS., & ShiramizuB.Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS2001; 15: 1801–1809.
7.
CherryC.L., GahanM.E., McArthurJ.C., LewinS.R., HoyJ.F., & WesselinghS.L.Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. Journal of Acquired Immune Deficiency Syndromes2002; 30: 271–277.
8.
IzutaS., SaneyoshiM., SakuraiT., SuzukiM., KojimaK., & YoshidaS.The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2’, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochemical & Biophysical Research Communications1991; 179: 776–783.
9.
MartinJ.L., BrownC.E., Matthews-DavisN., & ReardonJ.E.Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy1994; 38: 2743–2749.
10.
BrinkmanK., & KakudaT.N.Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?Current Opinion in Infectious Diseases2000; 13: 5–11.
11.
GalliM., RidolfoA.L., AdorniF., GervasoniC., RavasioL., CorsicoL., GianelliE., PiazzaM., VaccarezzaM., d'Arminio MonforteA., & MoroniM.Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1 infected patients treated with two nucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndromes2002; 29: 21–31.
12.
GalliM., PoloR., Saint MarcT., & WalliR., for the ART-associated Lipodystrophy European Collaborative Study (ALECS) Group. Guidelines to describe morphologic and metabolic alterations (MMA) under ART: the Marrakech classification. Nutrition & Metabolic Disorders in HIV Infection2002; 1: 25–29.
13.
PintiM., TroianoL., NasiM., MorettiL., MonterastelliE., MazzacaniA., MussiC., VenturaP., OlivieriF., FranceschiC., SalvioliG., & CossarizzaA.Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death & Differentiation2002; 9: 431–438.
14.
LeeH.C., YinP.H., LuC.Y., ChiC.W., & WeiY.H.Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochemical Journal2000; 348: 425–432.
15.
LedruE., ChristeffN., PateyO., de TruchisP., MelchiorJ.C., & GougeonM.L.Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood2000; 95: 3191–3198.
16.
Schulze-OsthoffK., BakkerA.C., VanhaesebroeckB., BeyaertR., JacobW.A., & FiersW.Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial function. Evidence for the involvement of mitochondrial radical generation. Journal of Biological Chemistry1992; 267: 5317–5323.
17.
HennetT., RichterC., & PeterhansE.Tumour necrosis factor-α induces superoxide anion generation in mitochondria of L929 cells. Biochemical Journal1993; 289: 587–592.
18.
PollaB.S., KantengwaS., MarièthozE., Jacquier-SarlinM., HennetT., Russo-MarieF., & CossarizzaA.TNF-α alters mitochondrial membrane potential in L929 but not in TNF-α-resistant L929.12 cells: relationship with the synthesis of heat shock proteins and superoxide dismutase activity. Free Radical Research1996; 25: 125–131.
19.
StaszewskiS., GallantJ.E., PozniakA.L., SuleimanJ.M.A.H., DeJesusE., LuB., SayreJ., & ChengA.Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results.10th Conference on Retroviruses & Opportunistic Infections (CROI), Chicago, Ill., USA, February 10–14 2003; Abstract 564b.
20.
ShiramizuB., WestgardE., CossarizzaA., PintiM., & ShikumaC.Competitive PCR-analysis of subcutaneous adipose tissue mtDNA from individuals with HAART-associated lipodystrophy.3rd International Workshop on Adverse Drug Reactions & Lipodystrophy in HIV, 2001; Athens, Greece.
21.
WalkerU.A., BickelM., Lütke VolksbeckS.I., KetelsenU-P, SchöferH., SetzerB., VenhoffN., RickertsV., & StaszewskiS.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes2002; 29: 117–121.
22.
CossarizzaA., MussiniC., & ViganòA.Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV anti-retroviral drugs: actors or bystanders?BioEssays2001; 23: 1070–1080.
23.
ZonL.I., ArkinC., & GroopmanJ-E. Haematologic manifestations of the human immune deficiency virus (HIV). British Journal of Haematology1987; 66: 251–256.
24.
PintiM., NasiM., MorettiL., BellodiC., TroianoL., MussiniC., EspositoR., & CossarizzaA.Role of platelet contamination in assessing mtDNA content in peripheral blood mononuclear cells. Antiviral Therapy2002; 7: L15.
25.
CossarizzaA.Tests for mitochondrial function and DNA: potentials and pitfalls. Current Opinions in Infectious Diseases2003; 16: 5–10.
